US Stock MarketDetailed Quotes
BIOR Biora Therapeutics
- 3.1600
- -0.1894-5.65%
Trading Nov 4 13:53 ET
13.71MMarket Cap-64P/E (TTM)
3.3400High3.0100Low41.43KVolume3.3100Open3.3494Pre Close129.87KTurnover1.30%Turnover RatioLossP/E (Static)4.34MShares19.900052wk High-0.15P/B10.11MFloat Cap3.010052wk Low--Dividend TTM3.20MShs Float3980.0000Historical High--Div YieldTTM9.85%Amplitude3.0100Historical Low3.1340Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Biora Therapeutics Stock Forum
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Biora Therapeutics (BIOR) announced progress on its BioJet™ Oral Delivery Platform at the 14th Annual PODD meeting. The company has successfully developed a smaller, 00-size BioJet device that can autonomously deliver medications to the small intestine. The technology has demonstrated >30% oral bioavailability ve...
📊⚡️📊
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
Biora Therapeutics (Nasdaq: BIOR) announced that CEO Adi Mohanty will present the company's new 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting in Boston, October 28–29, 2024. The company has successfully reduced the device size from 000 to 00 while increasing payload capacity, aligning with...
Biora Therapeutics Announces Positive Nasdaq Listing Decision
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that the company has been granted an extension to regain compliance with Nasdaq listing requirements.
"We shared with Nasdaq the upcoming company catalysts that we believe will drive significant value for shareholders, and we are pleased with their...
No comment yet